2024-11-07 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

This report provides a comprehensive analysis of Thermo Fisher Scientific Inc. (TMO) stock, covering various aspects including performance, financials, recent news, and overall outlook.

**1. Performance Analysis:**

* **Ticker:** TMO
* **Company:** Thermo Fisher Scientific Inc., a leading provider of scientific instruments, reagents, consumables, software, and services.
* **Cumulative Return:** 218.79%
* **S&P 500 (VOO) Cumulative Return:** 139.88%
* **Return Difference:** 78.91%
* **Relative Outperformance:** 36.97% (meaning TMO's performance is currently at the 36.97th percentile of its historical performance relative to S&P 500)

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|------|
| 2015-2017 | 48.2% | 14.4% | 18.0% | 1.1 |
| 2016-2018 | 61.3% | 17.3% | 36.6% | 1.1 |
| 2017-2019 | 126.1% | 17.3% | 83.0% | 1.1 |
| 2018-2020 | 141.4% | 24.6% | 102.3% | 0.8 |
| 2019-2021 | 204.1% | 24.6% | 114.3% | 0.8 |
| 2020-2022 | 68.7% | 26.2% | 51.0% | 0.8 |
| 2021-2023 | 12.5% | 33.2% | -16.3% | 0.9 |
| 2022-2024 | -13.2% | 31.0% | -36.9% | 0.9 |

**Analysis:**
* TMO consistently outperformed the market with a positive alpha throughout the analyzed period.
* Beta values suggest a moderate correlation with the overall market.

**2. Recent Price Action:**

* **Closing Price:** 559.68
* **5-Day Moving Average:** 556.04
* **20-Day Moving Average:** 574.43
* **60-Day Moving Average:** 598.06

**Analysis:**
* TMO's price is currently below all three moving averages, indicating a short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 26.45
* **PPO:** -0.1
* **Delta_Previous_Relative_Divergence:** -12.79 (Negative)
* **Expected Return:** 46.46%

**Analysis:**
* **RSI:** TMO is in oversold territory (below 30), suggesting potential for a rebound.
* **PPO:** Negative PPO confirms the short-term downtrend.
* **Delta_Previous_Relative_Divergence:** Indicates a recent short-term decline in relative performance.
* **Expected Return:** This suggests a strong long-term potential for outperforming S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2024-08-02 | 4.05 | 10.54 B$ |
| 2024-05-03 | 3.47 | 10.35 B$ |
| 2023-11-03 | 4.44 | 10.57 B$ |
| 2024-11-01 | 4.44 | 10.57 B$ |

**Analysis:**
* TMO consistently exceeded revenue expectations in recent quarters.
* Earnings have been relatively stable with slight fluctuations. 
* The most recent earnings report was not yet released, so we don't have access to the analysts' expectations.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.60B | 40.84% |
| 2024-06-30 | $10.54B | 41.24% |
| 2024-03-31 | $10.35B | 40.65% |
| 2023-12-31 | $10.89B | 40.35% |
| 2023-09-30 | $10.57B | 40.82% |

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $48.99B | 3.33% |
| 2024-06-30 | $47.43B | 3.26% |
| 2024-03-31 | $45.52B | 2.92% |
| 2023-12-31 | $46.73B | 3.49% |
| 2023-09-30 | $45.33B | 3.78% |

**Analysis:**
* Consistent strong revenue growth and healthy profit margins.
* Stable equity and moderate return on equity (ROE) show a solid financial foundation.

**6. News and Recent Issues:**

* **Recent Earnings:** TMO is expected to release its Q3 2024 earnings on November 1st.
* **Analyst Opinions:**  Analysts generally maintain a positive outlook on TMO, with many rating it as a "Buy" or "Strong Buy." They expect continued strong revenue growth and expansion in the diagnostics and life sciences markets.

**7. Summary & Overall Outlook:**

TMO is a fundamentally strong company with a long history of delivering consistent performance and exceeding expectations. 
* While the stock is currently experiencing a short-term decline, its long-term potential is still strong due to its dominance in the life science industry, expansion into new markets, and commitment to innovation. 
* TMO is well-positioned to benefit from growing global demand for diagnostics and laboratory services, as well as the rise of personalized medicine.
* The current downturn could be an attractive entry point for investors looking for a long-term growth stock.
* The expected return of 46.46% highlights its potential to outperform the market. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Before making any investment decisions, please consult with a qualified financial advisor.